长春西汀联合奥扎格雷钠治疗糖尿病合并急性脑梗死的疗效及安全性

Efficacy and Safety of Vinpocetine Combined with Sodium Ozagrel in Treatment of Diabetes Complicated with Acute Cerebral Infarction

目的:探讨长春西汀联合奥扎格雷钠治疗糖尿病合并急性脑梗死的疗效及安全性。方法:将2017年4月至2018年7月海南医学院第一附属医院收治的糖尿病合并急性脑梗死患者90例以随机数字表法分为对照组和观察组,每组45例。对照组患者采用奥扎格雷钠80 mg静脉滴注治疗;观察组患者采用奥扎格雷钠80 mg与长春西汀30 mg联合静脉滴注治疗,2周为1个疗程。比较两组患者的临床疗效、美国国立卫生院卒中神经功能缺损评分量表(national institutes of health stroke scale,NIHSS)评分、Barthel指数及血清可溶性细胞间黏附分子-1(sICAM-1)、白细胞介素6(IL-6)水平,记录不良反应发生情况。结果:观察组患者的总有效率为95.56%(43/45),明显高于对照组的82.22%(37/45),差异有统计学意义( P <0.05)。治疗后,观察组患者的NIHSS评分、Barthel指数、血sICAM-1水平和血IL-6水平分别为(4.19±2.17)分、(72.27±13.49)、(302.45±16.49)ng/ml和(11.24±2.13)ng/L,明显优于对照组的(7.68±2.41)分、(60.44±11.52)、(318.94±17.24)ng/ml和(13.21±2.31)ng/L,差异均有统计学意义( P <0.05)。观察组、对照组患者不良反应发生率分别为13.33%(6/45)、 15.56%(7/45),差异无统计学意义( P >0.05)。结论:奥扎格雷钠联合长春西汀治疗糖尿病合并急性脑梗死的疗效确切,有助于改善患者的神经功能和日常生活能力,降低血sICAM-1、IL-6水平,且患者可以耐受。

OBJECTIVE: To investigate the efficacy and safety of vinpocetine combined with sodium ozagrel in treatment of diabetes complicated with acute cerebral infarction. METHODS: Totally 90 patients with diabetes complicated with acute cerebral infarction admitted into the First Affiliated Hospital of Hainan Medical University from Apr. 2017 to Jul. 2018 were extractd to be divided into the observation group and the control group via the random number table, with 45 cases in each group. The control group was treated with 80 mg ozagrel sodium by intravenous drip, while the observation group received 80 mg ozagrel sodium and 30 mg vinpocetine combined with intravenous infusion for a course of 2 weeks. The clinical efficacy, national institutes of health stroke scale score(NIHSS), Barthel index, blood soluble intercellular adhesion mol-1(sICAM-1) and interleukin 6(IL-6) levels of two groups were compared, and adverse drug reactions were recorded. RESULTS: The total effective rate of the observation group was 95.56%(43/45), significantly higher than that of the control group(82.22%,37/45), with statistically significant difference(P<0.05). After treatment, the NIHSS score, Barthel index, blood sICAM-1 level and blood IL-6 level of the observation group were respectively(4.19±2.17) points,(72.27±13.49),(302.45±16.49) ng/ml and(11.24±2.13) ng/L, significantly better than those of the control group[(7.68±2.41)points,(60.44±11.52),(318.94±17.24) ng/ml and(13.21±2.31) ng/L, the difference was statistically significant(P<0.05). The incidence of adverse drug reactions in the observation group and the control group was 13.33%(6/45) and 15.56%(7/45), respectively, with no statistically significant difference(P>0.05). CONCLUSIONS: Ozagrel sodium combined with vinpocetine in treatment of diabetes complicated with acute cerebral infarction is effective, which is helpful to improve patients’ neurological function and ability of daily living, reduce the level of sICAM-1, IL-6, and the patients can tolerate.